Bristol educational outreach for Excedrin Migraine targeted to serious headache sufferers.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL EDUCATIONAL OUTREACH FOR EXCEDRIN MIGRAINE will be directed at consumers who want to learn more about serious headaches that may be migraines. Bristol-Myers Squibb estimates that upwards of 25 mil. Americans, mostly women (75%) and those in their 30s, suffer from headaches that could be classified as migraines, and that an estimated 17 mil. of those headache sufferers do not seek professional treatment. FDA's estimates of migraine sufferers are slightly lower, at 16 mil. to 18 mil., nonetheless, a large potential customer base for Excedrin Migraine.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning